← KYNTRA BIO, INC. (KYNB) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
KYNTRA BIO, INC. (KYNB)
Pharmaceutical Preparations · market cap $29M · as of 2026-07-18
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-09 (est.)
Earnings
Pipeline
13
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Kyntra Bio, Inc. (KYNB), formerly FibroGen, Inc., is a San Francisco-based biopharmaceutical company with a $30M market cap and 34 employees, reduced to a shell of its former self after late-stage failures, regulatory setbacks, and a data manipulation scandal that erased roughly $3.5B in value from its 2018–19 peak. The company retains a broad but largely legacy pipeline spanning anemia, fibrosis, and oncology, with only $37M in cash and an ~8-month runway. The single near-term catalyst is an August 10, 2026 earnings report rated low importance.
The catalyst path
- 2026-11-09 (est.)Earningsimp 5/10
- 2027-07-31 (est.)Phase 2 · FOR46imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| FG-4592 | Phase 3 | Anemia |
| Epoetin Alfa | Phase 3 | Anemia in End Stage Renal Disease |
| FG2216 | Phase 2 | Renal Anemia |
| Oral Iron | Phase 2 | Dialysis |
| FG-3246 | Phase 2 | Metastatic Castration-Resistant Prostate Cancer |
| SEPO® | Phase 3 | Chemotherapy Induced Anemia |
| Pamrevlumab | Phase 2 | Idiopathic Pulmonary Fibrosis |
| Roxadustat | Phase 3 | Anemia Associated With End Stage Renal Disease (ESRD) |
| FG-3019 | Phase 2 | Idiopathic Pulmonary Fibrosis |
| Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX | Phase 3 | Pancreatic Cancer Non-resectable |
| FOR46 | Phase 2 | Metastatic Castration-resistant Prostate Cancer |
| IV Iron | Phase 2 | Dialysis |
| Iron | Phase 3 | Anemia |
Price & technical context
3-month
-49.7%
6-month
-48.5%
12-month
-66.7%
52-wk range
$3.66–$11.03
vs 50-day MA
-42.6%
vs 200-day MA
-47.8%
Realized vol
55.5%
Max drawdown
-81.0%
Daily closes through 2026-11-05. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for KYNB (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 13 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.